Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Wart war: vitamin D3 or acyclovir injections – which works better?

NCT ID NCT07448844

Disease control Sponsor: Riphah International University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This study tests whether injecting acyclovir (an antiviral drug) or vitamin D3 directly into skin warts can clear them. Forty people aged 12 and older with common, plantar, flat, or nail warts will receive injections every two weeks for up to four sessions. The main goal is to see which treatment leads to complete wart clearance by week 8.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
acyclovir or vitamin D3 injected into the wart
What this could lead to
If it works, this could point toward a simple, affordable injection treatment for common skin warts.
What could go wrong
This is a small, early-phase trial with only 40 people, so results may not apply to everyone. Warts may come back, and injections can be painful or cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged 12 years and above with clinically diagnosed cutaneous warts * Common, plantar, flat, or periungual warts * Both treatment-naïve patients and those with recalcitrant warts Exclusion Criteria: * Pregnant or lactating women * Immunocompromised patients * Individuals with history of hypersensitivity to vitamin D3 or acyclovir * Individuals receiving systemic immunosuppressive or antiviral therapy * Patients with secondary infection at injection site * Patients who had received any topical or destructive treatment for wart in previous three months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Common wart are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

common wart plantar wart

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Common wart Common warts (verruca vulgaris) Flat wart Plantar wart Viral wart WART Warts hand Warts of foot

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Railway General Hospital, Railway Carriage Factory Rd, Railway Scheme 7, Rawalpindi

    RECRUITING

    Rawalpindi, Punjab Province, 46000, Pakistan

  • Riphah International Hospital, Islamabad Expy, Sector A DHA Phase 5, Islamabad

    RECRUITING

    Islamabad, 44000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.